Towards a better diagnosis and treatment of Rett syndrome: a model synaptic disorder

被引:74
作者
Banerjee, Abhishek [1 ]
Miller, Meghan T. [2 ]
Li, Keji [3 ]
Sur, Mriganka [3 ]
Kaufmann, Walter E. [4 ]
机构
[1] Univ Zurich, Brain Res Inst, Lab Neural Circuit Dynam, Zurich, Switzerland
[2] F Hoffmann La Roche & Cie AG, Roche Innovat Ctr, Roche Pharma Res & Early Dev, Basel, Switzerland
[3] MIT, Dept Brain & Cognit Sci, Picower Inst Learning & Memory, E25-618, Cambridge, MA 02139 USA
[4] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA
关键词
development; synapse; plasticity; autism; disorders; CPG-BINDING PROTEIN-2; MOUSE MODEL; DNA-METHYLATION; MECP2; MUTATION; INHIBITION; NEURONS; AUTISM; MICE; DEFICITS; REPRESSION;
D O I
10.1093/brain/awy323
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
With the recent 50th anniversary of the first publication on Rett syndrome, and the almost 20 years since the first report on the link between Rett syndrome and MECP2 mutations, it is important to reflect on the tremendous advances in our understanding and their implications for the diagnosis and treatment of this neurodevelopmental disorder. Rett syndrome features an interesting challenge for biologists and clinicians, as the disorder lies at the intersection of molecular mechanisms of epigenetic regulation and neurophysiological alterations in synapses and circuits that together contribute to severe pathophysiological endophenotypes. Genetic, clinical, and neurobiological evidences support the notion that Rett syndrome is primarily a synaptic disorder, and a disease model for both intellectual disability and autism spectrum disorder. This review examines major developments in both recent neurobiological and preclinical findings of Rett syndrome, and to what extent they are beginning to impact our understanding and management of the disorder. It also discusses potential applications of knowledge on synaptic plasticity abnormalities in Rett syndrome to its diagnosis and treatment.
引用
收藏
页码:239 / 248
页数:10
相关论文
共 109 条
  • [1] Deficiency of GABAergic synaptic inhibition in the Kolliker-Fuse area underlies respiratory dysrhythmia in a mouse model of Rett syndrome
    Abdala, Ana Paula
    Toward, Marie A.
    Dutschmann, Mathias
    Bissonnette, Johnm.
    Paton, Julian F. R.
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 2016, 594 (01): : 223 - 237
  • [2] Acadia Pharmaceuticals and Neuran Pharmaceuticals, 2018, ACADIA PHARM NEUR PH
  • [3] Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2
    Amir, RE
    Van den Veyver, IB
    Wan, M
    Tran, CQ
    Francke, U
    Zoghbi, HY
    [J]. NATURE GENETICS, 1999, 23 (02) : 185 - 188
  • [4] Anavex Life Sciences Corp, 2018, AN LIF SCI IN PHAS 2
  • [5] [Anonymous], 2017, RETT SYNDROME
  • [6] Correlation between clinical severity in patients with Rett Syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X-chromosome inactivation
    Archer, Hayley
    Evans, Julie
    Leonard, Helen
    Colvin, Lyn
    Ravine, David
    Christodoulou, John
    Williamson, Sarah
    Charman, Tony
    Bailey, Mark E. S.
    Sampson, Julian
    de Klerk, Nicholas
    Clarke, Angus
    [J]. JOURNAL OF MEDICAL GENETICS, 2007, 44 (02) : 148 - 152
  • [7] Increased Axonal Bouton Stability during Learning in the Mouse Model of MECP2 Duplication Syndrome
    Ash, Ryan T.
    Fahey, Paul G.
    Park, Jiyoung
    Zoghbi, Huda Y.
    Smirnakis, Stelios M.
    [J]. ENEURO, 2018, 5 (03)
  • [8] Jointly reduced inhibition and excitation underlies circuit-wide changes in cortical processing in Rett syndrome
    Banerjee, Abhishek
    Rikhye, Rajeev V.
    Breton-Provencher, Vincent
    Tang, Xin
    Li, Chenchen
    Li, Keji
    Runyan, Caroline A.
    Fu, Zhanyan
    Jaenisch, Rudolf
    Sur, Mriganka
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (46) : E7287 - E7296
  • [9] Banerjee Abhishek, 2012, Front Psychiatry, V3, P34, DOI 10.3389/fpsyt.2012.00034
  • [10] Arbaclofen in fragile X syndrome: results of phase 3 trials
    Berry-Kravis, Elizabeth
    Hagerman, Randi
    Visootsak, Jeannie
    Budimirovic, Dejan
    Kaufmann, Walter E.
    Cherubini, Maryann
    Zarevics, Peter
    Walton-Bowen, Karen
    Wang, Paul
    Bear, Mark F.
    Carpenter, Randall L.
    [J]. JOURNAL OF NEURODEVELOPMENTAL DISORDERS, 2017, 9